The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Generative AI as a Strategic Enabler for Global Start-Ups Entering Southeast Asian Markets: Capabilities, Illustrative Cases, ...

CBSE Class 12 practical examinations for the 2026 board exams are being scheduled in many schools during the second half of ...

An Ensemble Learning Tool for Land Use Land Cover Classification Using Google Alpha Earth Foundations Satellite Embeddings ...

Which Premier League managers and players are in the mix for the end-of-season awards? Let's pick the front-runners for each ...

Catching you up on the most notable product releases from the world's biggest consumer electronics show: CES 2026.